Emicizumab prophylaxis in infants: Single‐centre experience
British Journal of Haematology · 2024
DOI: 10.1111/bjh.19312 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Haematology, 2024. Verfasst von Sarina Levy-Mendelovich und 8 weiteren Autor:innen. Beteiligte Einrichtung: National Haemophilia Center and Thrombosis & Hemostasis Institute, Sheba Medical Center, Ramat Gan, Israel. Hauptthemen laut MEDLINE: Hemophilia A, Antibodies, Bispecific, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 29 Literaturangaben.
Abstract (Originalsprache)
The hallmark of haemophilia A (HA) therapy is prophylaxis, aimed at spontaneous bleeding prevention. Emicizumab provides a viable alternative to intravenous factor replacement therapy. However, data on its use in infants are limited. This single‐centre open arm prospective study reports on emicizumab prophylaxis in infants. We included severe HA patients under 1 year who started emicizumab prophylaxis since 2018, with longitudinal follow‐up. The study collected data on demographics, clinical and laboratory variables, the occurrence of bleeding events, surgeries and treatment outcomes. Of the 27 enrolled infants, whose median age at prophylaxis initiation was 7 months, 24 primarily choose to start emicizumab therapy (3/27 switched from FVIII prophylaxis due to development of FVIII inhibitors). The median age for prophylaxis initiation decreased to 3 months in 2023. Following emicizumab initiation, the median calculated ABR decreased, and no intracranial haemorrhages were observed. Thrombin generation showed a significant improvement in peak height and endogenous thrombin potential at steady state after a loading period. Our study highlights a shift towards early prophylaxis in the era of non‐replacement therapies. It underscores the need for continuous evaluation and refinement of treatment approaches, emphasizing personalized care and diligent monitoring in the evolving field of paediatric haemophilia care.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- National Haemophilia Center and Thrombosis & Hemostasis Institute, Sheba Medical Center, Ramat Gan, Israel.
- Faculty of Medicine, Amalia Biron Research Institute of Thrombosis & Hemostasis, Tel Aviv University, Tel Aviv, Israel.
- Talpiot Medical Leadership Program, Sheba Medical center, Ramat Gan, Israel.
- Department of Paediatric Hematology-Oncology, The Edmond and Lily Safra Children's Hospital, Sheba Medical Center, Ramat Gan, Israel.
- Department of Internal Medicine, Division of Hematology/Oncology, University of Iowa, Iowa City, Iowa, USA.
- Department of Medicine and Surgery, University of Insubria, Varese, Italy.
ORCID-Profile: Sarina Levy-Mendelovich, Assaf Arie Barg, Gili Kenet
Zitieren
APA
Levy-Mendelovich, S., Greenberg-Kushnir, N., Budnik, I., Barg, A. A., Cohen, O., Avishai, E., Barazani-Brutman, T., Livnat, T., & Kenet, G. (2024). Emicizumab prophylaxis in infants: Single‐centre experience. British Journal of Haematology. https://doi.org/10.1111/bjh.19312
Vancouver
Levy-Mendelovich S, Greenberg-Kushnir N, Budnik I, Barg AA, Cohen O, Avishai E, et al. Emicizumab prophylaxis in infants: Single‐centre experience. British Journal of Haematology. 2024. doi:10.1111/bjh.19312
BibTeX
@article{LevyMendelovich2024,
author = {Levy-Mendelovich, Sarina and Greenberg-Kushnir, Noa and Budnik, Ivan and Barg, Assaf Arie and Cohen, Omri and Avishai, Einat and Barazani-Brutman, Tami and Livnat, Tami and Kenet, Gili},
title = {Emicizumab prophylaxis in infants: Single‐centre experience},
journal = {British Journal of Haematology},
year = {2024},
doi = {10.1111/bjh.19312}
}
EUVIMED